Market Overview

Celgene Says ABRAXANE Demonstrates Statistically Significant Improvement

Related CELG
Celgene Corporation Rallies Following JP Morgan Upgrade
Benzinga's Top Upgrades
Celgene Boasts Of An Impressive Pipeline (Seeking Alpha)

Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III study of ABRAXANE^® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone.

Posted-In: News FDA


Related Articles (CELG)

View Comments and Join the Discussion!

Get Benzinga's Newsletters